Introduction
Donor-recipient disparities at the allelic level of the HLA-DRB1 gene are considered as a risk factor for adverse reactions in hematopoietic SCT (HSCT).
1,2
Although the HLA-DRB1 four-digit matching is important for maximizing the success of unrelated HSCT, a possibility exists that amino acid mismatches, located outside the Ag binding groove, may be permissive. Uncertainty still remains about the impact of HLA-DRB3 mismatch in unrelated HSCT.
In principle, only the non-synonymous nucleotide transitions occurring in exon 2 of the DRB1 gene should be considered functionally relevant in HSCT, as only the b1 domain is directly involved in alloimmune recognition. 3 However, a doubt still persists whether an amino acid replacement in the HLA-DRb2 domain, subsequent to a nucleotide substitution in exon 3 of the gene, is determinant in the outcome of HSCT. Virtually, it seems unlikely, although not excludable, as a non-conservative amino acid change occurring in the HLA-DRb2 domain may alter the affinity of the HLA-DR molecule for the CD4 coreceptor, hamper the activation signal trasduction in T cells and influence the immune response. 4 In October 2005, the World Health Organization nomenclature committee officially assigned the name HLA-DRB1*14:54 to a novel allele that differs from the closest HLA-DRB1*14:01 just for the T4C transition at nucleotide 51 in exon 3. 5 This mutation leads to an amino acid change, from tyrosine to histidine, in the b2 domain of the DR molecule at residue 112. On the basis of the crystal structure of an HLA-DR-T cell receptor complex, the polymorphism does not appear to be in a crucial position, being in a loop located near the cell surface and not at the site for Ag binding or in a position to affect the interaction with the T cell receptor. Nevertheless, the residue 112 is near the site involved in CD4 binding and a substitution of a Tyr with a His, with different steric hindrance, may alter the interaction with CD4 and the intramolecular salt bridge between H112 and E162.
At the moment, only hypotheses, based on computational analysis, have been made to calculate the impact of HLA-DRB1*14:01/*14:54 donor-recipient mismatch in HSCT. 6 Here, we would like to verify, with real cases, the involvement of amino acid substitution outside the Ag binding groove on the outcome of HSCT.
Starting from 2006, all immunogenetics laboratories were able to distinguish these two different alleles irrespective of the commercial kits that they used for high-resolution typing. Soon it was evident that the new variant DRB1*14:54 was quite common in all populations, and almost threefold more frequent than the HLA-DRB1*14:01 allele. 7, 8 It was also observed that the two alleles were in tight linkage disequilibrium with different HLA-DRB3 variants. Namely, DRB1*14:01 was linked to DRB3*02:01, whereas DRB1*14:54 was linked to DRB3*02:02. 6 This finding complicated the transplant eligibility criteria, adding the question whether the HLA-DRB1, DRB3 haplotype mismatch between donor and recipient could be accepted or should be refused. To this, it was imperative to speculate whether the dual mismatch had a greater impact than the single one in HSCT.
At the proteomic level, the heterodimers encoded by the HLA-DRB3*02:02 and *02:01 alleles differ from each other at residues 86 in the b1 domain and 164 in the b2 domain. 9 Although amino acid 164 is far from the peptide binding site, amino acid 86 is an anchor residue, located in the Ag binding groove as a part of the pocket p1. The glycine/valine dimorphism at this position is crucial for peptide recognition and has been functionally implicated in susceptibility to several autoimmune diseases. 10, 11 With regard to the steric conformation at the p1 pocket, HLA-DRB3*02:01 should be much more selective than DRB3*02:02 in peptide anchoring. In fact, it carries a valine dimorphism that makes the p1 pocket smaller, and excludes large aromatic and hydrophobic residues from binding. It is intriguing to speculate whether this change in the pocket backbone of HLA-DRB3 has a role in HSCT. Although the HLA-DRB3 gene is expressed at lower levels than HLA-DRB1, the DRB3 heterodimers are efficient peptide-presenter molecules. 12, 13 A different amino acid sequence in the binding groove could influence the allorecognition process, which is the basis of transplant-related adverse sequelae. The cooperation of multiple transplant centers was essential to reach a discrete number of cases for the statistical analysis, considering that the HLA-DRB1*14 allele displays a general low frequency in most populations. 14 Information about main donors' and patients' characteristics (age, gender, disease status at HSCT, year of transplantation), number of HLA mismatches other than HLA-DRB1*14 and the status of matching for HLA-DRB3 was collected and summarized in Table 1 . Acute leukemia in first CR, chronic myeloid leukemia in the first chronic phase and non-malignant hemopathies were grouped as 'early' disease at HSCT (N ¼ 32); all the others were considered 'advanced' (N ¼ 71).
Patients and methods

Patients and donors
In all, 76 patient-donor pairs matched at DRB1*14, whereas 27 did not. Only 99 pairs were evaluable for HLA-DRB3: 74 matched and 25 mismatched. The HLA class I high-resolution typing was available for 80% of patientdonor pairs when the study commenced. The remaining 20% was retrospectively studied at the four-digit level during the study. In all, 37 pairs were 10/10 fully matched at a high-resolution level, the others differed variably at HLA class I.
HLA-DRB1*14 and DRB3* high-resolution typing Using historical DNAs, all donor-recipient pairs were subtyped for HLA-DRB1*14 and, when not carried out before, also for HLA-DRB3. Typing was carried out by the PCR-sequence specific primer method using high-resolution commercial kits able to recognize all the allelic variants 
Statistical analysis
The w 2 -and Mann-Whitney U-tests were used when appropriate to compare clinical variables. The KaplanMeier method was used for estimation of OS and DFS; 15 cumulative incidence was used for estimation of TRM; values were provided together with the respective 95% confidence interval (CI); rates of aGvHD and cGvHD were calculated as well. aGvHD was graded according to Glucksberg criteria. 16 Cox regression analysis evaluated any possible correlation between HLA-DRB1*14:01/*14:54 mismatch, HLA-DRB3*02:01/*02:02 mismatch or DRB1, DRB3 haplotype mismatch and HSCT outcome, after adjustment for the above-mentioned variables. 17 A P-value o0.05 was considered as significant.
Results
A total of 31 HLA-DRB1*14-and/or DRB3-mismatched pairs were found, of which 21 were mismatched for both HLA-DRB1*14 and HLA-DRB3, six were mismatched only for DRB1*14 and four only for DRB3.
Main patients' and donors' characteristics are shown in Table 1 . Pairs were divided into two main groups, depending on whether they were HLA-DRB1*14 matched (N ¼ 76) or mismatched (N ¼ 27). No significant differences among the two sets were observed; however, the HLA-DRB3 matching was significantly higher in DRB1*14 identical pairs than in the mismatched ones: 68/76 (89.47%) vs 6/27 (22.22%), Po0.0001.
The following were diagnosed: acute myeloid leukemia (n ¼ 23), acute lymphoblastic leukemia (n ¼ 22), chronic myeloid leukemia (n ¼ 12), chronic lymphocytic leukemia (n ¼ 3), myelodysplastic syndrome (n ¼ 3), multiple myeloma (n ¼ 9), myeloproliferative syndrome other than chronic myeloid leukemia (n ¼ 3), non-Hodgkin's lymphoma (n ¼ 7), Hodgkin's lymphoma (n ¼ 5), secondary acute leukemia (n ¼ 1), solid tumor (n ¼ 1), inherited immunodeficiency (n ¼ 5), hemoglobinopathy (n ¼ 5), aplastic anemia (n ¼ 4).
Median follow-up of all patients was 47 months (range: 17-148). The median rate of 5-year OS was 39% (95% CI: 29-49), without significant difference between HLA-DRB1*14-matched and -mismatched couples: 40% (95% CI: 28-52) matched and 37% (95% CI: 17-57) mismatched (Figure 1 ).
Cumulative incidence of TRM was 44% (95% CI: 33-55). No significant difference existed between DRB1*14-matched and -mismatched pairs (Figure 2) .
The data on aGvHD were available for 91 patients. The rate of grade 2-4 aGvHD was 41.76% (38/91) in the entire sample, 41.54% (27/65) in HLA-DRB1*14 matched and 45.45% (10/22) in DRB1*14 mismatched (P ¼ NS). The rate of grade 3-4 aGvHD was 23.08% (21/91) in the whole sample, and 21.54% (14/65) in HLA-DRB1*14-matched and 27.27% (6/22) in HLA-DRB1*14-mismatched groups, without statistically significant differences.
A total of 79 patients were evaluable for cGvHD (alive 4100 days after HSCT): of these, nine (11%) presented limited and 18 (22%) extensive forms without significant differences in the two DRB1*14-matched or -mismatched subsets (P ¼ 0.15).
Overall 5-year DFS was 34% (95% CI: 25-43), 31% (95% CI: 12-50) in HLA-DRB1*14 matched and 35% (95% CI: 24-46) in DRB1*14 mismatched (P ¼ 0.86) (Figure 3) .
Finally, the HSCT outcome was evaluated according to matching at DRB3: no significant differences were observed, neither in OS nor in TRM (P ¼ 0.60 and P ¼ 0.23, respectively). The data on aGvHD were available for 87 Among the HLA-DRB3-matched group, 5-year DFS was 37% (95% CI: 25-49) and, among the HLA-DRB3-mismatched ones, it was 27% (95% CI: 9-45) (P ¼ 0.59).
With regard to the DRB1, DRB3 cis-combination, we confirmed a higher frequency of the HLA-DRB1*14:54, DRB3*02:02 haplotype with respect to the HLA-DRB1*14:01, DRB3*02:01 one in both recipients and donors. However, in 11 pairs, either the donor or the recipient was found to carry mixed haplotypes, namely, HLA-DRB1*14:01, DRB3*02:02 or HLA-DRB1*14:54, DRB3*02:01 (Table 2) . When comparing these pairs with the remaining 88 for OS or TRM, no differences were observed (P ¼ 0.61 and P ¼ 0.25, respectively). Interestingly, considering the nine patients with haplotypes unambiguously assessed through family studies, we observed that the unusual combinations recurred more frequently in HLA-B*51-positive haplotypes (5/9 recipients).
Cox regression adjusted for patients' age (above and below the median), gender, diagnosis (early vs advanced), year of HSCT and HLA allele matching other than DRB confirmed that there was no significant difference on OS or TRM, according to DRB1*14 or DRB3 or haplotype mismatch. On the contrary, age 433 years and the advanced disease status at HSCT were associated significantly with worse outcome after the transplant. Results are shown in Table 3 .
Discussion
To understand the functional importance of the amino acid substitutions outside the Ag recognition site of HLA-DR molecules in HSCT, we used, as a model, 103 unrelated pairs, transplanted in Italy, and typed as HLA-DRB1*14:01 before 2006, when it was impossible to define the HLA-DRB1*14:54 most common variant. The use of exon 3 primers now allows unambiguous distinction of these alleles. We did not find any significant difference in transplant outcome between patient/donor pairs matched vs mismatched at DRB1*14.
At the protein level, the products of the HLA-DRB1*14:01 and DRB1*14:54 alleles share the amino acid sequence of their b1 domain, but are different in the b2 domain at residue 112. This is the result of a nucleotide substitution at position 51, which exchanges codon from TAC to CAC and leads to an amino acid replacement of the mature HLA molecule from Tyr of DRB1*14:01 to His of the more frequent DRB1*14:54. Similar to HLA-DRB1*14:01 and DRB1*14:54, another set of DR alleles is identical in the combinatory site, but differs in the mature protein. It is the case of the HLA-DRB1*12:06 variant, found in the Korean population and presenting only a difference in the b2 domain with respect to HLA-DRB1*12:01. 18 However, owing to the negligible frequency of HLA-DRB1*12:06 with respect to DRB1*12:01 in the general population, we decided not to propose this study in an Italian cohort of transplants. 19 Here, we confirmed the recent observation by Lee and Furst that the linkage disequilibrium between the HLA-DRB1*14 and DRB3*02 alleles is not absolute. 20, 21 In addition, we found four people (two recipients and two donors) with the haplotype HLA-DRB1*14:54, DRB3*02:01, never reported so far, and this added further variability to the two-locus organization of the HLA-DRB1*14 haplotype among different populations. When we further extended the analysis to the HLA-B locus, we observed that the uncommon two-loci haplotypes Because of the low frequency of the HLA-DRB1*14 allele, working in a group was essential to reach a number of couples sufficiently large for statistical analysis. Our findings suggest that mismatches outside the HLA-DRB1 Ag binding groove, as well as those related to HLA-DRB3*02 alleles, are not significantly associated with adverse reactions in both directions. On the contrary, in spite of the great variability of the sample, patients' age and disease status conditioned the OS and TRM significantly, representing a good positive control.
Here, we envisaged in a sample of transplanted recipients (median follow-up 4 years) that the HLA-DRB1*14:01/ HLA-DRB1 exon 3 and DRB3 mismatch in unrelated HSCT A Pasi et al *14:54 and HLA-DRB3*02:01/*02:02 recipient-donor mismatching, either alone or combined, did not clinically translate into significantly higher TRM or mortality in our cohort. Although HLA-DRB1 donor-recipient allele diversity must still be highly regarded, there is increasing evidence of the existence of permissive incompatibilities, so that peculiar structural diversities among HLA class II molecules may be accepted. 22 Computational algorithms have been created to predict the response to vaccines and the tolerance to solid organ allogeneic transplants, on the basis of the immunogenicity of HLA epitopes and on peptide fitting to the groove; however, in an HSCT setting, they remain elusive. [23] [24] [25] Moving from virtual to real practice, our data suggest that, although differing in the pocket's anchor residue, the HLA-DRB3*02:01-and *02:02-expressed products are likely to be unable to induce an appreciable immune response in the complex context of stem cell transplant. That is probably dependent on the low level of expression of these molecules at the cell surface, but one cannot exclude their involvement in other contexts, such as in disease predisposition.
Despite the great variability of recipients' clinical parameters, the findings in our cohort suggest that HLA-DRB1*14:01/*14:54 and DRB3*02:01/*02:02 mismatches do not influence the outcome of HSCT in terms of OS, TRM, DFS, aGvHD and cGvHD. Nevertheless, larger studies, ideally involving international collaborations, will be needed to widen our understanding of the influence of HLA-DRB1*14:01/*14:54 and HLA-DRB3*02:01/*02:02 mismatches in unrelated HSCTs.
